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Abstract: 
Pathway analysis has lead to a new era in genomic research by providing further biological process information compared to 
traditional single gene analysis. Beside the advantage, pathway analysis provides some challenges to the researchers, one of which 
is the quality of pathway data itself. The pathway data usually defined from biological context free, when it comes to a specific 
biological context (e.g. lung cancer disease), typically only several genes within pathways are responsible for the corresponding 
cellular process. It also can be that some pathways may be included with uninformative genes or perhaps informative genes were 
excluded. Moreover, many algorithms in pathway analysis neglect these limitations by treating all the genes within pathways as 
significant. In previous study, a hybrid of support vector machines and smoothly clipped absolute deviation with groups-specific 
tuning parameters (gSVM-SCAD) was proposed in order to identify and select the informative genes before the pathway 
evaluation process. However, gSVM-SCAD had showed a limitation in terms of the performance of classification accuracy. In order 
to deal with this limitation, we made an enhancement to the tuning parameter method for gSVM-SCAD by applying the B-Type 
generalized approximate cross validation (BGACV). Experimental analyses using one simulated data and two gene expression data 
have shown that the proposed method obtains significant results in identifying biologically significant genes and pathways, and in 
classification accuracy. 
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Background: 
Incorporation of prior pathway data into microarray analysis 
has become a popular research area in bioinformatics due to the 
advantages in providing the further biological interpretation 
compared to the single gene microarray analysis. These 
advantages have triggered various experiments and approaches 
in order to identify informative genes and pathways that 
contribute to certain cellular processes. Two most common 
approaches to identify the informative genes and pathways are 
enrichment analysis (EA) and machine learning (ML) 
approaches  [1]. In EA approaches, genes are viewed as 
functional pathways where the pathways with large number of 
differentially expressed genes between two conditions are 
considered as significant [1]. While in ML approaches, the genes 
in the pathways are discriminated between two or more 
phenotypes of interests and the pathway with genes that 
improves the prediction of the phenotype considered as 
significant pathways. 
 
However, there are some challenges in pathway analysis, such 
as, some pathways may be included with uninformative genes 
or perhaps informative genes were excluded [1]. Another 
concern is that usually pathway data are curated from the 
biological context free; it can be that only several genes take 
part in certain cellular process when it goes to the phenotype 
s p e c i f i c  a n a l y s i s  ( e . g .  l u n g  c a n c e r  r e s e a r c h ) .  I n  o r d e r  t o  d e a l  
with the challenges in the quality of pathway data, several 
researchers in EA approaches attempt to refining the pathway BIOINFORMATION  open access 
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data to specific conditions by removing the unaltered genes in 
the pathways, and including the additional information of the 
functional interpretation of the pathways or gene groups [1]. In 
ML approaches, several researchers have included the gene 
selection methods in order to select the informative genes 
within pathways before the pathway evaluation process [2, 3]. 
This is because, gene selection methods provide several 
advantages such as: (1) improves the classification accuracy, (2) 
removes uninformative genes, and (3) reduces computational 
time [13]. 
 
Misman  et al. [4] had proposed the gSVM-SCAD in order to 
identify the significant genes and pathways, simultaneously 
dealing with the challenges in pathway data quality. gSVM-
SCAD is a hybrid method of support vector machines (SVM) 
and smoothly clipped absolute deviation (SCAD) with group-
specific tuning parameters that select the informative genes 
within pathways before the pathway evaluation process. gSVM-
SCAD had shown its superior performance in identifying 
significant genes and pathways compared to the hybrid of SVM 
and L1 penalty function (L1 SVM), and almost with all other 5 
classifiers without gene selection methods [4]. However, in this 
work, we detected that gSVM-SCAD had some limitations. 
 
A SCAD performance relies on the tuning parameter. If the 
tuning parameter is too small, it can bring little sparsity and 
over fit to the classifier model. While if it is too large, it can 
make very sparse to the classifier model but produced poor 
discriminating power [5, 6]. Therefore, it is important to choose 
an appropriate tuning parameter selector method for the gSVM-
SCAD, since the SCAD plays an important role in determining 
the true classification model for the SVM. The generalized cross 
validation (GCV) proposed by Fan and Li. [5] is widely used in 
the past literatures as a tuning parameter selector method for 
SVM-SCAD. Unfortunately, GCV had some limitations where it 
poorly performs when dealing with the low number of 
variables (genes) and large sample sizes [6]. This is due to the 
reason that usually some pathways contained not more than 
100 genes and even some pathways contained less than 10 
g e n e s .  W e  b e l i e v e d  t h a t  t h i s  s c e n a r i o  c a n  l e a d  t o  t h e  p o o r  
performance of SCAD in selecting the informative genes and 
simultaneously identifying significant genes. In order to 
surmount the limitation of the gSVM-SCAD, we propose the B-
type generalized approximate cross validation (BGACV) as a 
new tuning parameter selector method for gSVM-SCAD. Our 
proposed method is denoted as gSVM-SCADBGACV. 
 
Methodology: 
Experimental Data: 
There are two types of data used: gene expression and pathway 
data. For gene expression data, the canine and lung cancer 
datasets were used to evaluate the performance of the gSVM-
SCADBGACV (the information of the datasets is shown in 
Table 1, see supplementary material). For the pathway data, 
there are total of 441 pathways with 129 taken from KEGG 
database while other 312 pathways curated from BioCarta 
database. Both gene expression and pathway data can be 
downloaded at http://bioinformatics.med.yale.edu/pathway-
analysis/datasets.htm. For the simulated data, total 1060 
simulated genes are generated, where 848 genes are informative 
while other 212 genes are uninformative. The sample size for 
this experiment has been setup as 80. All 1060 genes are 
distributed into the Gi groups of genes where i = 1,...,15 and 
each group have a different size of genes. For the distribution of 
genes, each Gi contains i x 10 of genes. Moreover, 80% of genes 
in each group are informative. This creates 15 groups of genes 
with sizes varying from 10 to 150. The simulation data were 
created using the sim.data function in R package penalized 
SVM [14]. 
 
gSVM-SCAD with BGACV Tuning Parameter Method (The 
Proposed Method): 
Our proposed method (gSVM-SCADBGACV) consists of three 
steps as shown in Figure 1. Step 1: group genes based on the 
pathway information provided by the pathway data. Step 2 is 
the most important step where the genes within pathways are 
evaluated using the SVM-SCAD, the uninformative genes are 
discarded from their pathway. In step 2.1, the proposed 
BGACV is used in order to select an appropriate tuning 
parameter for SVM-SCAD. In step 3, the classification error 
from the selected genes for each pathway is calculated. Step 1 
and 3 is similar to the gSVM-SCAD but in step 2.1, there are 
some changes where BGACV is used instead of GACV.  
 
 
Figure 1: The gSVM-SCADBGACV procedure. 
 
BGACV is a modified version of GACV where “B” stands for 
Bayesian information criterion (BIC) model selector proposed 
by Schwarz [9]. Researchers believe that solution provided by 
BGACV is sparse and analogous to BIC [6]. The first BIC type of 
GCV for SCAD had been proposed by Wang et al. [10] and 
improved by Wang et al. [11] to be more robust when dealing 
with the diverging number of parameters. Despite showing BIOINFORMATION  open access 
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good results when dealing with the diverging number of 
parameters, Wang et al. [11] admitted that their method still 
showed some limitation when dealing with the data with high 
number of samples and low number of variables. Therefore, we 
used the GACV formula [12] and transformed the GACV 
form ula into B GACV. The GACV  prove d it robustnes s when 
dealing with data with high number of samples and low 
number of variables [12]. T h e  f o r m u l a  o f  G A C V  i s  g i v e n  i n  
supplementary material. 
 
 
Figure 2: Correlations between the tuning parameter selector 
methods performance and the number of genes. 
 
Discussion: 
Simulation Study: 
The purpose of this experiment is to evaluate the performance 
of both GACV and BGACV and providing the appropriate for 
gSVM-SCAD in a situation where the sizes of pathways are 
small and medium. Both gSVM-SCADBGACV and gSVM-
SCAD were run for 10 times for each group of genes and the 
averages of the classification error are recorded. The results are 
presented in Figure 2. 
 
From the Figure 2, it is shown that BGACV obtained less 
classification error compared to GACV in group of genes sizes 
10, 20, and 60 with 0.02, 0.06, and 0.06 less, respectively. All 
these groups of genes contained a size of genes smaller than the 
sample size (sample size = 80). While for the groups of genes 
that contained the size of genes with equal and bigger than 
sample size, there are no different results between both BGACV 
and GACV methods. From the results above, it is shown that 
BGACV can deal with the small group of genes compared to 
GACV by producing less misclassification error. While for 
groups of genes that contained l a r g e r  s i z e  o f  g e n e s  t h a n  t h e  
sample size, both BGACV and GACV methods have the same 
performance. Our analysis shows that BGACV are more robust 
and consistent in providing the near optimal for SCAD when 
dealing with the diverging numbers of parameters, especially 
when the number of genes are smaller than the number of 
samples. 
 
Performance Evaluation: 
A gSVM-SCADBGACV is also used on the lung cancer and 
canine datasets to evaluate the performance of the proposed 
method. From this experiment, results from the 10-fold cross 
validation (10-fold CV) were recorded and compared with other 
5 supervised machine learning methods. The 5 supervised 
machine learning methods are PathwayRF [15], neural 
networks, k-nearset neighbour with 1 neighbour (KNN1) and 3 
neighbours (KKN3), and linear discriminant analysis (LDA). 
The results of the gSVM-SCADBGACV performance against 
other machine learning methods are shown in Table 2  (see 
supplementary material). 
 
For the canine dataset in Table 2 (see supplementary material), 
it is interesting to note that gSVM-SCADBGACV outperforms 
gSVM-SCAD and the other machine learning methods with 
85.95% accuracy. The gSVM-SCADBGACV achieved 4.87% 
higher than gSVM-SCAD, 3.62% higher than neural networks, 
slightly 0.04% higher than PathwayRF, and 4.96% higher than 
KNN1 and KNN3 respectively, and 9.34% higher than LDA. For 
the lung cancer dataset, gSVM-SCADBGACV also showed a 
significant improvement with 76.55% accuracy and 2.78% 
higher than gSVM-SCAD. While with other methods, gSVM-
SCADBGACV obtained 4.55% higher than PathwayRF, 6.16% 
higher than neural networks, 14.82% higher than KNN1, 11.75% 
higher than KNN3, 13.31% higher than LDA, 21.41% higher 
than L1 SVM, 23.05% higher than SVM-SCAD. 
 
From these results, it is proved that BGACV plays an important 
role in increasing the performance of SCAD in gSVM-SCAD. 
For the canine dataset, gSVM-SCAD showed quite poor 
performance, ranked third behind neural networks and 
PathwayRF. However, when BGACV is applied to the gSVM-
SCAD, it showed a significant improvement even it obtained 
slightly higher than PathwayRF result. This is because, BGACV 
is consistently identified nearly optimal for SCAD and 
simultaneously provides nearly unbiased coefficient estimation 
when dealing with large coefficients. The results from the 
gSVM-SCADBGACV show significant achievement, since the 
pathway analysis usually dealing with the lower size of genes 
and larger size of samples. 
 
Conclusion: 
In this work, the proposed gSVM-CADBGACV is shown to 
outperform the gSVM-SCAD and other supervised machine 
learning methods. It is also shown that, a tuning parameter 
selector method plays an important role in gSVM-SCAD in 
dealing with the small genes size and large sample size that 
usually happened in pathway-based microarray analysis. The 
gSVM-SCADBGACV consistently showed better performance 
from the simulation study, the 10-fold CV accuracy, and in 
biological validation compared to gSVM-SCAD (see 
supplementary material for biological validation results). We 
have only focused on static gene expression data; however, our 
approach can be implemented with modification to time-course 
or survival gene expression data. 
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Supplementary material: 
 
The formula of GACV is shown below: 
 
Where n, β , and λ  refers to number of samples, coefficients of the hyperplane, and tuning parameter, respectively while DFλ is the 
degree of freedom of parameter λ, where 
 
 
 
Where   and   is the reproducing kernel hilbert space (RKHS) with SVM reproducing kernel 
K [12]. Acording to Shi et al. [6], in the transformation akaike information criterion (AIC) to BIC, BIC replaces degree of freedom, 
DFλ with  . Therefore, the BGACV can be defined as, 
 
The nearly optimal tuning parameter λ is obtained by minimizing the error rate from the BGACV. 
 
 
Table 1: Gene expression datasets 
Name  No. of samples  No. of genes  Class  Reference 
Lung 86  7129  2(normal  and  tumor)  [7] 
Canine  31  12473  2(control and drug induced dogs)  [8] 
 
Table 2: A comparison of averages 10-fold CV accuracies from the top ten pathways with other supervised machine learning 
methods for the lung cancer and canine datasets. 
 
Method 
10-fold CV (%) 
Canine   Lung cancer 
   gSVM-SCADBGACV 85.96  76.55 
   gSVM-SCAD (Misman et al., 2010) 81.08  73.77 
   PathwayRF (Pang et al., 2006) 85.92  71.00 
   Neural Networks  82.33 70.39 
   KNN1  81.00 61.73 
   KNN3  81.00 64.80 
   LDA  76.62 63.24 
   L1 SVM  72.33 55.14 
   SVM-SCAD  73.67       53.5 
Note: The texts in Bold are the highest 10-fold CV accuracy. The texts in italic are the methods from the self-running experiment. 
 
Biological Validation: 
The five most significant pathways in the lung cancer dataset are (1) WNT signaling pathway, (2) AKAP95 role in mitosis and 
chromosome dynamics pathway, (3) Induction of apoptosis pathway, (4) Antisense pathway, and (5) Cycling of Ran in 
nucleocytoplasmic transport pathway as shown in Table 3. For the WNT signaling pathway, Mazieres et al. [1] reported that the 
pathway plays a significant role in the development of lung and other colorectal cancers. With respect to the second pathway, it 
also contributes to the development of lung cancer, since the AKAP95 protein plays an important role in cell mitosis [2]. The gSVM-
SCAD identifies that induction of apoptosis pathway as one of the lung cancer related pathway, where this pathway has been 
reported by Lee et al. [3] as one of the contributor to the lung cancer development. For the Keratinocyte Differentiation pathway, 
Massion et al. [4] had shown that this pathway has contributed to the development of lung cancer. While for the Activation of Csk 
pathway, Masaki et al. [5] have reported that the activation of this pathway plays an important role in the development of lung 
cancer, with three genes marked as lung cancer genes. The selected genes for each pathway are also presented in Table 3. BIOINFORMATION  open access 
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Table 3: Selected genes from the top five pathways in the lung cancer dataset 
Pathways No.  of 
genes 
Selected gene(s) 
WNT Signaling Pathway  24  APC [1], HNF1A [6], CREBBP [7], HDAC1 [8], MYC [1], WNT1 [9], CSNK1A1 [10], 
AXIN1 [1], CSNK2A1 [10], CTNNB1 [1], GSK3B [1], TLE1 [11], PPARD, PPP2CA, 
TAB1, DVL1 
AKAP95 role in mitosis and 
chromosome dynamics  
10  DDX5 [12], PRKACB [10], CDK1 [13], CCNB1 [14], PPP2CA, PRKAR2B, PRKAR2A 
Induction of apoptosis   36  FADD [15], TNFSF10 [16], CASP7 [3], BCL2 [17], BIRC3 [18], CASP9 [3], TRAF [19], 
BIRC [20], CASP8 [3], CASP3 [3], TNFRSF25 [21], CASP10 [3], RARA [22], CASP6 
[3], TRADD, RELA, DFFA, RIPK1 
Keratinocyte Differentiation  45  Hras [23], FASLG [24], ETS1 [25], JUN [26], MAPK14 [27], BCL2 [28], MAPK8 [29], 
EGFR [30], RAF1 [31], FAS [32], RELA, PRKCQ, PPP2CA, MAP2K6, NFKB1, CEBPA 
Activation of Csk  30  PRKACB [10], CREBBP [7], HLA-DQB1 [10], CD247, IL23A, PRKAR1B, GNGT1, 
CD3D, CD3E 
Note: The genes in italic text are uninformative. The genes in bold text are genes that directly related to the lung cancer. 
 
For the canine dataset as shown in Table 4, the gSVM-CADBGACV has been detected. Four pathways are similar to the pathways that 
are detected by Pang et al.  [33]; the pathways are Aminoacyl-tRNA biosynthesis pathway, Granzyme A mediated Apoptosis 
Pathway, TGF-beta signaling pathway, and Antisense Pathway. Hence, all these four pathways are considered significant based on 
the literature. For the Starch and Metabolism pathway, it may not seem directly related to vascular pathology, but it contained two 
genes that related to the metastasis for gene RUVBL2 [34] and inflammation for UGDH [35]. This makes it possible that this 
pathway may relate to the vascular pathology and thus prompting biologists to conduct further research on this pathway. The 
selected genes for each pathway are presented in Table 4. Fifteen genes were selected, with thirteen genes detected as informative. 
 
Table 4: Selected genes from the top five pathways in the canine dataset 
Pathways  No. of genes  Selected gene(s) 
TGF-beta signaling pathway  40  RHOA [33], BMP4 [33], SP1 [33] 
Starch and sucrose metabolism  59  TESK1, RUVBL2 [34], UGDH [35] 
Aminoacyl-tRNA biosynthesis  19  NARS [33], FARS [33], FARSA [33] 
Granzyme A mediated Apoptosis Pathway  5  SET, APEX1 [33], DFFB [33] 
Antisense Pathway  34  SFPQ  [33], MATR3 [33], ADAR [33] 
Note: The genes in italic text are uninformative. The genes in bold vascular injury in coronary arteries related. 
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